Michael Ehlers

Biogen has appointed Michael Ehlers as executive vice president of research and development. He will report to CEO George Scangos and will begin his tenure in late May. Ehlers joins Biogen from Pfizer where he served as group senior vice president for biotherapeutics research and development and CSO for the company's Neuroscience and Pain Research Unit. Prior to joining Pfizer in 2010, he was a professor of neurobiology and an investigator at the Howard Hughes Medical Institute at Duke University Medical Center.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.